International Leukemia Target Board

ConditionsRelapsed Hematologic Malignancy Refractory Hematologic Malignancy

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age0-25

SponsorPrincess Maxima Center for Pediatric Oncology

About this trial

The iLTB is a proof-of-concept initiative for children with r/r hematological malignancies, in which available treatment options will be prioritized by actionable events in a harmonized and uniform setting across Europe by a team of biologists, bio-statisticians, bio-informaticians, disease experts, geneticists, flow-experts, clinical trial physicians and also the treating physician.

The iLTB will discuss molecular (genetic lesions), immunophenotypic/surface antigen markers information and, if available, drug response profiles to prioritize these events taking into account the treatment history and treatment intention (bridging to hematopoietic stem cell transplanation/CAR-T or palliative) of each patient followed by a registry to monitor how often iLTB advice has been followed, which other therapy was chosen (off-label, compassionate use) and what the patient outcome is at an aggregated level.

As such the iLTB is non-interventional as it mainly provides advice and registers data on patients discussed in the iLTB.

Eligibility criteria

Qualifiers

The patient has been diagnosed with a R/R hematological malignancy;

The patient is less than 18 years of age at the time of first diagnosis and less than 25 years at the time of inclusion with relapse/refractory hematological malignancy;

The patient is treated in a pediatric/AYA setting or study protocol, with no current standard of care treatment;

The patients' life expectancy is at least 6 weeks;